Critical role for matrix metalloproteinase-9 in platelet-activating factor-induced experimental tumor metastasis

International Journal of Cancer

Volumn 120, Issue 6, 2007, Pages 1277-1283

  Ko, Hyun Mi ^a,b   Kang, Jee Hae ^a   Jung, Bongnam ^a   Kim, Han A ^a   Sung, Jun Park ^a   Kim, Kyoung Jin ^a   Kang, Yeong Rim ^a   Lee, Hern Ku ^b   Im, Suhn Young ^a  

^a Chonnam National University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

AP 1; Matrix metallproteinases; Metastasis; NF B; Platelet activating factor

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PARTHENOLIDE; PROTEIN C JUN; SMALL INTERFERING RNA; THROMBOCYTE ACTIVATING FACTOR; TRANSCRIPTION FACTOR AP 1;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; BRONCHUS MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NF-KAPPA B; PLATELET ACTIVATING FACTOR; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-1;

EID: 33846968127     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22450     Document Type: Article

References (48)

1. Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
2. Woessner JF, Jr. MMPs and TIMPs - an historical perspective. Mol Biotechnol 2002;22:33-49.
3. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
4. Gay JC. Mechanism and regulation of neutrophil priming by platelet-activating factor. J Cell Physiol 1993;156:189-97.
5. Fukuda AI, Breuel KF. Effect of platelet activating factor on embryonic development and implantation in the mouse. Hum Reprod 1996;11:2746-9.
6. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J 1992;6:2296-301.
7. Buttke TM, Sandstrom PA. Redox regulation of programmed cell death in lymphocytes. Free Radic Res 1995;22:389-97.
8. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev 1987;39:97-145.
9. Maggi M, Bonaccorsi L, Finetti G, Carloni V, Muratori M, Laffi G, Forti G, Serio M, Baldi E. Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A. Cancer Res 1994;54:4777-84.
10. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neoangiogenesis. Am J Pathol 2000;157:1713-25.
11. Mannori G, Barletta E, Mugnai G, Ruggieri S. Interaction of tumor cells with vascular endothelia: role of platelet-activating factor. Clin Exp Metastasis 2000;18:89-96.
12. Tripathi YB, Kandala JC, Guntaka RV, Lim RW, Shukla SD. Platelet activating factor induces expression of early response genes c-fos and TIS-1 in human epidermoid carcinoma A-431 cells. Life Sci 1991;49:1761-7.
13. Montrucchio G, Lupia E, Battaglia E, Del Sorbo L, Boccellino M, Biancone L, Emanuelli G, Camussi G. Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arterioscler Thromb Vasc Biol 2000;20:80-8.
14. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski MR, Bosia A, Albini A, et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 1995;96:940-52.
15. Fallani A, Grieco B, Barletta E, Mugnai G, Giorgi G, Salvini L, Ruggieri S. Synthesis of platelet-activating factor (PAF) in transformed cell lines of a different origin. Prostaglandins Other Lipid Mediat 2002;70:209-26.
16. Denizot Y, Descottes B, Truffinet V, Valleix D, Labrousse F, Mathonnet M. Platelet-activating factor and liver metastasis of colorectal cancer. Int J Cancer 2005;113:503-5.
17. Pitton C, Lanson M, Besson P, Fetissoff F, Lansac J, Benveniste J, Bougnoux P. Presence of PAF-acether in human breast carcinoma: relation to axillary lymph node metastasis. J Natl Cancer Inst 1989;81:1298-302.
18. Im SY, Ko HM, Kim JW, Lee HK, Ha TY, Lee HB, Oh SJ, Bai S, Chung KC, Lee YB, Kang HS, Chun SB. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res 1996;56:2662-5.
19. Ko HM, Kang JH, Choi JH, Park SJ, Bai S, Im SY. Platelet-activating factor induces matrix metalloproteinase-9 expression through Ca(2+)-or PI3K-dependent signaling pathway in a human vascular endothelial cell line. FEBS Lett 2005;579:6451-8.
20. Shan L, Nishimura Y, Kotani Y, Yokoyama M. Platelet-activating factor increases the expression of metalloproteinase-9 in human bronchial epithelial cells. Eur J Pharmacol 1999;374:147-56.
21. Takafuji S, Ishida A, Miyakuni Y, Nakagawa T. Matrix metalloproteinase-9 release from human leukocytes. J Investig Allergol Clin Immunol 2003;13:50-5.
22. Tao Y, Bazan HE, Bazan NG. Platelet-activating factor induces the expression of metalloproteinases-1 and -9, but not -2 or -3, in the corneal epithelium. Invest Ophthalmol Vis Sci 1995;36:345-54.
23. Axelrad TW, Deo DD, Ottino P, Van Kirk J, Bazan NG, Bazan HE, Hunt JD. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J 2004;18:568-70.
24. Deo DD, Bazan NG, Hunt JD. Activation of platelet-activating factor receptor-coupled G α q leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J Biol Chem 2004;279:3497-508.
25. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
26. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999;274:29130-7.
27. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κ. FEBS Lett 1998;435:29-34.
28. Esteve PO, Chicoine E, Robledo O, Aoudjit F, Descoteaux A, Potworowski EF, St-Pierre Y. Protein kinase C-ζ regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-α in glioma cells via NF-κB. J Biol Chem 2002;277:35150-5.
29. Knipp BS, Ailawadi G, Ford JW, Peterson DA, Eagleton MJ, Roelofs KJ, Hannawa KK, Deogracias MP, Ji B, Logsdon C, Graziano KD, Simeone DM, et al. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-κB and activator protein-1 activity. J Surg Res 2004;116:70-80.
30. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003;369:485-96.
31. Lee JG, Dahi S, Mahimkar R, Tulloch NL, Alfonso-Jaume MA, Lovett DH, Sarkar R. Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci USA 2005;102:16345-50.
32. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994;91:4293-7.
33. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002;86:1876-83.
34. Lee PP, Hwang JJ, Murphy G, Ip MM. Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 2000;141:3764-73.
35. MacDougall JR, Bani MR, Lin Y, Rak J, Kerbel RS. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 1995;55:4174-81.
36. Ueda Y, Imai K, Tsuchiya H, Fujimoto N, Nakanishi I, Katsuda S, Seiki M, Okada Y. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol 1996;148:611-22.
37. Kossakowska AE, Hinek A, Edwards DR, Lim MS, Zhang CL, Breitman DR, Prusinkiewicz C, Stabbler AL, Urbanski LS, Urbanski SJ. Proteolytic activity of human non-Hodgkin's lymphomas. Am J Pathol 1998;152:565-76.
38. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
39. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000;86:204-7.
40. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001;65:55-61.
41. Moses MA. The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180-9.
42. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
43. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertropic chondrocytes. Cell 1998;93:411-22.
44. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
45. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.
46. Ko HM, Seo KH, Han SJ, Ahn KY, Choi IH, Koh GY, Lee HK, Ra MS, Im SY. NF-κB dependency of platelet-activating factor-induced angiogenesis. Cancer Res 2002;62:1809-14.
47. 2. Biochim Biophys Acta 2006;1761:1093-9.
48. Wei WZ, Ratner S, Fulton AM, Heppner GH. Inflammatory infiltrates of experimental mammary cancers. Biochim Biophys Acta 1986;865:13-26.